Evolus, Inc.
NASDAQ:EOLSDrug Manufacturers - Specialty & Generic
-$0.14 today
- Market cap
- $467.95M
- Beta
- 1.33
- P/E (TTM)
- -9.9
- EPS (TTM)
- -$0.67
Volume 0.80M
Average 0.86M
EOLS Total Liabilities
Everything the company owes to creditors and other parties.
Evolus, Inc.NASDAQ: EOLS
Total Liabilities · Q1 FY2026 · quarter ended Mar 2026
Total liabilities rises 13.4% from a year ago
Total liabilities stood at $249.43M at the end of Q1 FY2026, up 13.4% from a year earlier and up 0.2% from the prior quarter. Over 3 fiscal years it compounded at +16.0% a year.
Context
- Total liabilities amounted to 113.0% of total assets at the end of Q1 FY2026, up 9.9 pp from a year earlier.
- Total liabilities increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether total liabilities keeps rising in the next quarterly balance sheet after a +13.4% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 248.97M USD
- Year-over-year change
- +9.7%
- 4-year CAGR
- +9.1%
| Period | Period end | Total Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 248.97M | +9.7% |
| FY2024 | 2024-12-31 | 227.05M | +8.3% |
| FY2023 | 2023-12-31 | 209.69M | +31.5% |
| FY2022 | 2022-12-31 | 159.48M | -9.2% |
| FY2021 | 2021-12-31 | 175.61M | — |
Total Liabilities vs competitors
How EOLS compares with its peers on the latest reported figures
No competitor Total Liabilities figures are available to compare.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 146.26M | 53.92M | 62.84M | 86.95M | 53.83M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 |
| Net Receivables | 14.66M | 22.45M | 30.53M | 47.68M | 54.7M |
| Inventory | 1.76M | 18.85M | 11M | 12.16M | 26.96M |
| Other Current Assets | 11.04M | 1.68M | 2.36M | 1.2M | 3.67M |
| Total Current Assets | 178.8M | 100.8M | 112.42M | 151.34M | 142.92M |
| Property, Plant & Equipment (Net) | 4.09M | 4.56M | 7.85M | 10.41M | 12.5M |
| Goodwill | 21.21M | 21.21M | 21.21M | 21.21M | 21.21M |
| Intangible Assets | 50.63M | 48.6M | 47.11M | 48.75M | 48.04M |
| Long-term Investments | 0 | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 2.76M | 2.81M | 409K | 858K | 1.2M |
| Total Non-current Assets | 78.68M | 77.18M | 76.58M | 81.23M | 82.95M |
| Total Assets | 257.48M | 177.98M | 189M | 232.57M | 225.87M |
| Account Payables | 6.09M | 8.94M | 4.27M | 9.24M | 23.36M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 7.93M | 9.01M | 11.03M | 14.45M | 11.55M |
| Other Current Liabilities | 0 | 0 | 18.18M | 0 | 1.3M |
| Total Current Liabilities | 57.66M | 46.51M | 48.29M | 62.96M | 75.31M |
| Long-term Debt | 71.22M | 71.88M | 120.36M | 121.51M | 146.1M |
| Deferred Tax Liabilities | 40K | 22K | 27K | 6K | 28K |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 44.43M | 39.85M | 36.2M | 35.82M | 21.17M |
| Total Non-current Liabilities | 117.94M | 112.98M | 161.4M | 164.09M | 173.67M |
| Total Liabilities | 175.61M | 159.48M | 209.69M | 227.05M | 248.97M |
| Common Stock | 1K | 1K | 1K | 1K | 1K |
| Retained Earnings | (422.88M) | (497.29M) | (558.98M) | (609.4M) | (661.04M) |
| Accumulated OCI | 0 | (337K) | (427K) | (905K) | (156K) |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 81.88M | 18.5M | (20.69M) | 5.52M | (23.11M) |
| Total Debt | 74.74M | 74.42M | 126.55M | 129.98M | 155M |
| Net Debt | (71.51M) | 20.5M | 63.71M | 43.03M | 101.17M |
Evolus, Inc.
NASDAQ:EOLS
Intrinsic Alpha fair value
Locked
Current Price
$7.07
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.